CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$3.09
-0.29 (-8.58%)
▼
5d:
-14.88%
30d:
-16.49%
90d:
-17.6%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLLS is down 14.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLLS is down 14.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $3.09, which is considered oversold relative to its 30-day fair value range of $3.52 to $3.98.
Technical Outlook: Technically, CLLS is in a downtrend. The price is currently testing key support at $3.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+146.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLLS is in a downtrend. The price is currently testing key support at $3.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+146.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.52 -
$3.98
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.6%)
- BULLISH: Trading 146.0% below Wall St target ($7.60)
- WARNING: Recommendation downgraded due to -14.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.52 -
$3.98
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.05
Resistance Level
$3.80
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.49
Wall Street Target
$7.60
(+146.0%)
Revenue Growth (YoY)
-37.3%
Profit Margin
-89.5%
Share & Embed Analysis
Last updated: June 03, 2026 6:18 PM ET
Data refreshes hourly during market hours. Next update: 7:18 PM
Data refreshes hourly during market hours. Next update: 7:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 53 HOLD |
